Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Academician O. Ghudusha… | Healthcare Services | 26.4% | 87th pct | 268 |
| K. Eristavi National Ce… | Healthcare Services | 24.2% | 84th pct | 268 |
| West Georgia Medical Ce… | Healthcare Services | 15.6% | 66th pct | 268 |
| American Hospital Netwo… | Healthcare Services | — | no FY data | 268 |
| High Medical Technologi… | Healthcare Services | — | no FY data | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 3 of 5 peers filed FY2024. Switch to FY2022 (5 of 5).
| Ratio — FY 2024 | K. Eristavi National Ce… | Academician O. Ghudusha… | West Georgia Medical Ce… | American Hospital Netwo… | High Medical Technologi… |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 81.7% | 68.7% | 29.7% | — | — |
| EBITDA Margin | 24.2% | 26.4% | 15.6% | — | — |
| EBITDAR | 13,653 | 12,374 | 7,141 | — | — |
| EBITDAR Margin | 24.2% | 26.4% | 15.6% | — | — |
| EBIT Margin | 7.6% | 21.0% | 9.7% | — | — |
| Net Profit Margin | 6.7% | 23.6% | 17.0% | — | — |
| Operating Expense % of Sales | 58.3% | 42.2% | 15.4% | — | — |
| Returns | |||||
| Return on Assets (ROA) | 3.5% | 13.2% | 7.8% | — | — |
| Return on Equity (ROE) | 4.8% | 13.9% | 9.1% | — | — |
| ROIC [EBIT / Invested Capital] | |||||
| 4.9% |
| 13.8% |
| 5.4% |
| — |
| — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 11.2% | 0.0% | 0.0% | — | — |
| Debt-to-Equity | 0.15x | 0.00x | 0.00x | — | — |
| Debt-to-EBITDA | 0.88x | 0.00x | 0.00x | — | — |
| Equity-to-Assets | 74.2% | 95.4% | 85.3% | — | — |
| Net Debt | 8,339 | -8,544 | -1,865 | — | — |
| Cash & Equivalents | 3,677 | 8,544 | 1,865 | — | — |
| Total Debt | 12,016 | N/A | N/A | — | — |
| Liquidity & working capital | |||||
| Current Ratio | 1.23x | 4.20x | 1.56x | — | — |
| Quick Ratio | 1.06x | 3.44x | 1.29x | — | — |
| Cash Ratio | 0.24x | 2.20x | 0.13x | — | — |
| Total Current Assets | 19,292 | 16,308 | 22,705 | — | — |
| Total Current Liabilities | 15,625 | 3,879 | 14,591 | — | — |
| Inventory | 2,656 | 2,946 | 3,931 | — | — |
| Trade Receivables | 12,959 | 4,819 | 11,888 | — | — |
| Trade Payables | 10,733 | 2,696 | 1,958 | — | — |
| Net Working Capital | 3,666 | 12,429 | 8,114 | — | — |
| Net Working Capital % of Revenue | 6.5% | 26.6% | 17.7% | — | — |
| Trade Working Capital | 4,881 | 5,068 | 13,861 | — | — |
| Trade Working Capital % of Revenue | 8.7% | 10.8% | 30.3% | — | — |
| Change in Trade Working Capital | N/A | N/A | N/A | — | — |
| Turnover & efficiency | |||||
| Inventory Turnover | 3.89x | 4.98x | 8.18x | — | — |
| Days Inventory Outstanding (DIO) | 93.9 | 73.3 | 44.6 | — | — |
| Receivables Turnover | 4.35x | 9.71x | 3.85x | — | — |
| Days Sales Outstanding (DSO) | 84.0 | 37.6 | 94.9 | — | — |
| Payables Turnover | 0.96x | 5.44x | 16.41x | — | — |
| Days Payable Outstanding (DPO) | 379.4 | 67.1 | 22.2 | — | — |
| Cash Conversion Cycle | -201.6 days | 43.8 days | 117.3 days | — | — |
| Asset Turnover | 0.53x | 0.56x | 0.46x | — | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | 14,573 | 16,458 | 11,560 | — | — |
| Free Cash Flow (OCF − Capex proxy) | 3,402 | 17,395 | 1,526 | — | — |
| Cash Conversion (OCF / EBITDA) | 106.7% | 133.0% | 161.9% | — | — |
| Dividends Declared | 0 | 21,951 | 8,806 | — | — |
| Dividend Payout Ratio | 0.0% | 198.8% | 113.6% | — | — |